Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Vaccines01:30

Cancer Vaccines

348
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
348

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental p38 MAPK inhibitors for the treatment of urological cancers: observations from early clinical trials.

Expert opinion on investigational drugs·2026
Same author

Management of urinary stones by experts in stone disease (ESD 2025).

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2025
Same author

The feasibility and acceptability of a (mobile) application for men with lower urinary tract symptoms: a pilot study.

Minerva urology and nephrology·2025
Same author

Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece.

Current oncology (Toronto, Ont.)·2025
Same author

Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.

European urology·2025
Same author

Relugolix for the treatment of prostate cancer.

Expert opinion on pharmacotherapy·2024

Related Experiment Video

Updated: Jun 19, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

PSMA-based therapeutics for prostate cancer.

Panagiotis Velissarios Stamatakos1, Charalampos Fragkoulis1, Aggeliki Leventi1

  • 1Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece.

Expert Opinion on Pharmacotherapy
|July 26, 2024
PubMed
Summary

Prostate-specific membrane antigen (PSMA) radiolabels are transforming prostate cancer treatment, moving from imaging to targeted radionuclide therapy. Further research is needed to optimize dosage and safety for broader application.

Keywords:
CRPCPSMAprostate cancerradioligand therapytheranostics

More Related Videos

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Related Experiment Videos

Last Updated: Jun 19, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate cancer (PCa) is a leading male malignancy, traditionally treated with surgery, radiotherapy, or hormonotherapy.
  • Prostate-specific membrane antigen (PSMA) radiolabels have significantly advanced PCa diagnosis and treatment.
  • PSMA-targeted approaches offer a new paradigm in managing prostate cancer.

Purpose of the Study:

  • To review the evolving role of PSMA radiolabels in prostate cancer management.
  • To discuss the transition of PSMA tracers from diagnostic imaging to therapeutic applications.
  • To highlight ongoing research and future directions in PSMA-targeted theranostics.

Main Methods:

  • Literature review of PSMA radiolabels in prostate cancer.
  • Analysis of PSMA tracers in imaging and therapy.
  • Examination of current clinical applications and ongoing trials.

Main Results:

  • PSMA tracers initially served diagnostic imaging purposes.
  • PSMA is now utilized with cytotoxic isotopes (e.g., Lutetium-117, Actinium-225) for radioligand immunotherapy.
  • Ongoing trials explore novel radionuclides and ligands for PSMA-targeted therapy.

Conclusions:

  • PSMA radioligand therapy is currently approved for metastatic prostate cancer.
  • Investigating PSMA radioligand therapy for earlier stages requires addressing dosage, dosimetry, and safety.
  • Future well-designed studies are essential to fully realize PSMA theranostics potential.